GlobeNewswire Inc.··Hagens BermanAardvark Therapeutics Stock Crashes 56% as Lead Drug Halted Over Cardiac Safety
Aardvark Therapeutics ($AARD) plummeted 56% after pausing Phase 3 HERO trial for ARD-101 due to cardiac safety concerns, contradicting prior safety assurances.
AARDstock declinesecurities investigation